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ABSTRACT Burkholderia pseudomallei causes signiﬁcant global morbidity and mor-
tality, with the highest disease burden in parts of Asia where culture-based diagno-
sis is often not available. We prospectively evaluated the Active Melioidosis Detect
(AMD; InBios International, USA) lateral ﬂow immunoassay (LFI) for rapid detection of
B. pseudomallei in turbid blood cultures, pus, sputum, sterile ﬂuid, urine, and sera.
The performance of this test was compared to that of B. pseudomallei detection us-
ing monoclonal antibody latex agglutination (LA) and immunoﬂuorescence assays
(IFA), with culture as the gold standard. AMD was 99% (99/100; 95% conﬁdence in-
terval, 94.6 to 100%) sensitive and 100% (308/308; 98.8 to 100%) speciﬁc on turbid
blood culture bottles, with no difference from LA or IFA. AMD speciﬁcity was 100%
on pus (122/122; 97.0 to 100%), sputum (20/20; 83.2 to 100%), and sterile ﬂuid (44/
44; 92 to 100%). Sensitivity on these samples was as follows: pus, 47.1% (8/17; 23.0
to 72.2%); sputum, 33.3% (1/3; 0.84 to 90.6%); and sterile ﬂuid, 0% (0/2; 0 to 84.2%).
For urine samples, AMD had a positive predictive value of 94% (32/34; 79.7 to
98.5%) for diagnosing melioidosis in our cohort. AMD sensitivity on stored sera, col-
lected prospectively from melioidosis cases during this study, was 13.9% (5/36; 4.7%
to 29.5%) compared to blood culture samples taken on the same day. In conclusion,
AMD is an excellent tool for rapid diagnosis of melioidosis from turbid blood cul-
tures and maintains speciﬁcity across all sample types. It is a promising tool for uri-
nary antigen detection, which could revolutionize diagnosis of melioidosis in
resource-limited settings. Further work is required to improve sensitivity on non-
blood culture samples.
KEYWORDS B. pseudomallei, melioidosis, blood, lateral ﬂow immunoassay, pus, rapid
diagnosis, serum, sputum, sterile ﬂuid, urine
Burkholderia pseudomallei is a saprophytic bacterium causing melioidosis, a diseasewith diverse clinical manifestations, including fulminant septicemia, pneumonia,
meningo-encephalitis, abscess formation, septic arthritis, and more-indolent cutaneous
presentations (1). The global burden of melioidosis has been estimated at 165,000
cases/year with 89,000 fatalities (2). The highest known burden of disease is in south
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and southeast Asia, where case fatality rates reach around 40% (3), and even in
countries with advanced health care systems such as Australia, mortality reaches 14%
(4). In the Lao People’s Democratic Republic (Laos), increasing numbers of cases have
been recognized since the disease was ﬁrst diagnosed in 1999 (5), and more than 100
cases of culture-conﬁrmed melioidosis are now being identiﬁed at Mahosot Hospital
Microbiology Laboratory each year with peak incidence during the rainy season (6).
Culture is currently the gold standard diagnostic test for melioidosis, with 100%
speciﬁcity but an estimated sensitivity of only 60% (7). However, culture conﬁrmation
takes a minimum of 48 to 72 h (7) and requires speciﬁc media for optimal sensitivity in
nonsterile samples (8) and laboratory containment and expertise often not available in
areas of endemicity. B. pseudomallei is intrinsically resistant to many antibiotics, and
therefore melioidosis does not respond to most agents used for empirical treatment of
sepsis, pneumonia, and abscesses in developing countries (9). Therefore, life-saving
treatment is often fatally delayed if a speciﬁc diagnosis cannot be conﬁrmed. Simple,
rapid diagnostic tests for melioidosis for use directly on clinical samples are needed, not
only for improving patient outcomes but also to improve epidemiological surveillance
of melioidosis and thereby strengthen public health interventions. Immunoﬂuores-
cence to detect B. pseudomallei directly in clinical samples (10) and latex agglutination
for rapid identiﬁcation of positive cultures (11, 12) are used in some areas where
melioidosis is endemic. However, these tests require equipment, expertise, and re-
agents that are not widely available. More recently, an immunochromatographic lateral
ﬂow rapid diagnostic test (RDT) to detect B. pseudomallei extracellular polysaccharide
antigen directly in clinical samples has been developed (Active Melioidosis Detect
[AMD]; InBios, USA) (13). The method is simple, rapid (results are available within 15
min), and relatively inexpensive (estimated cost, $2/test) and does not require addi-
tional equipment; in addition, the kit may be stored at room temperature, making it
ideal for use in resource-limited settings. To date, this kit has undergone only limited
clinical evaluations (13, 14). We evaluated the diagnostic performance of AMD on a
variety of clinical samples (including blood culture broths, pus, sterile ﬂuid, sputum, and
urine) over two rainy seasons from patients with suspected and culture-conﬁrmed
melioidosis presenting to Mahosot Hospital, Vientiane, Laos.
MATERIALS AND METHODS
Analytical sensitivity and speciﬁcity. The limit of detection of the AMD test was assessed using
seeded blood cultures and quantitative culture techniques. A single colony of B. pseudomallei (clinical
isolate) was taken from a 24- to 48-h culture, and a 0.5 McFarland standard suspension was made using
5 ml phosphate-buffered saline (PBS). This was diluted to 1:1,000,000, and then 1 ml was inoculated into
each of 4 negative blood culture bottles (Pharmaceutical factory No. 2, Vientiane, Laos [15]), and the
bottles were shaken gently to mix and incubated aerobically at 35 to 37°C. From the time of inoculation
(time zero) and every 12 hours thereafter, blood culture broths were observed for turbidity, Gram
staining was performed using standard methods, and AMD and quantitative culture were performed.
AMD was performed in duplicate on paired uncentrifuged and centrifuged samples from each blood
culture broth as follows: 0.5 ml of blood culture broth mixture was dispensed into a 1.5-ml Eppendorf
tube, 1 drop of lysis buffer was added, and the suspension was gently mixed using a micropipette. A
20-l volume of this suspension was then applied to the AMD test strip, followed by 3 drops of chase
buffer. The result was read after 15 min according to the manufacturers’ instructions (Appendix 1). For
centrifuged samples, 1 ml of blood culture broth was centrifuged at 845  g (3,000 rpm on microcen-
trifuge 5424 from Eppendorf) for 10 min, after which the pellet was resuspended in 1 drop of lysis buffer,
and 20 l of this suspension was applied to the AMD test strip and read as described above. All
centrifugation was carried out under biosafety containment level 3 conditions.
Quantitative culture was performed using the Miles et al. method (16): 1 ml was removed from each
of the seeded blood culture broths after 0, 12, and 24 h of incubation. Each 1 ml was diluted 1:10 in PBS
8 times to make dilutions of 101 to 108 concentrations. A 20-l volume of each of these dilutions was
pipetted onto 1/6 of a blood agar plate, allowed to dry for 20 to 30 min, and then incubated aerobically
at 35 to 37°C for 24 h. Each dilution was tested in triplicate. The CFU per milliliter was calculated for each
seeded blood culture as the average number of colonies for the dilution where the highest numbers of
discrete colonies (between 10 and 100) were clearly seen, multiplied by 50 dilution factor. The result
of the quantitative culture was recorded and compared to AMD positivity across the panel of 4 seeded
blood cultures to estimate the limit of detection of AMD.
To investigate analytical speciﬁcity, negative blood culture broths were seeded (as above) with a
range of NCTC/ATCC reference organisms (Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC
700603, Klebsiella oxytoca NCTC 8167, Enterobacter aerogenes NCTC 10006, Enterobacter cloacae NCTC
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11580, Citrobacter freundii NCTC 9750, Edwardsiella tarda NCTC 10396, Salmonella enterica serovar Typhi
NCTC 786, S. enterica serovar Enteritidis ATCC 13076, Pseudomonas aeruginosa ATCC 27853, Acinetobacter
baumannii NCTC 12156, Ochrobactrum anthropi NCTC 12168, Aeromonas hydrophila NCTC 8049, Yersinia
enterocolitica NCTC 11175, Vibrio cholerae NCTC 8021, Burkholderia thailandensis NR-9908, Burkholderia
cepacia NCTC 10743, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis NCTC 11047), soil
isolates of Burkholderia thailandensis, and Lao clinical isolates of B. pseudomallei and Burkholderia cepacia
(see Table S2 in the supplemental material). Broths were incubated aerobically at 35 to 37°C and
observed daily for turbidity. AMD was performed on uncentrifuged samples from turbid blood culture
broths (as previously described).
Prospective evaluation. (i) Study population. Between 26 June and 18 December 2014, all turbid
blood cultures and pus and sputum samples received at Mahosot Hospital Microbiology Laboratory,
Vientiane, Laos, were included. Sterile ﬂuid samples received between 10 October and 18 December
2014 were also included. All routine urine samples received between 2 July and 2 September 2014 were
included in order to provide baseline speciﬁcity data. After an interim analysis, selected urine samples
only were included (3 September to 18 December 2014 and 23 June to 12 November 2015). The criterion
for selection was the presence of1 of the following clinical details: suspected or conﬁrmed melioidosis;
diabetes mellitus and sepsis or fever; prostatitis; or lung, liver, or spleen abscess. Only the ﬁrst urine
sample received from a patient was included.
Stored admission sera from patients diagnosed with melioidosis by culture from any sample between
26 June and 18 December 2014 were retrospectively tested by AMD in June 2015.
Sample processing. All samples were processed for microscopy and culture according to standard
laboratory procedures (CLSI). B. pseudomallei was isolated from clinical samples using standard media
(goat blood, chocolate, and MacConkey agars) and speciﬁc selective media (Ashdown’s agar and
modiﬁed Ashdown’s selective broth [8]). Each set of blood cultures sent from a patient at any one time
contained two blood broth culture bottles (Pharmaceutical factory No. 2, Vientiane, Laos [15]), which
were incubated aerobically at 35 to 37°C and observed daily for turbidity for up to 7 days.
Blood cultures. AMD was performed on all turbid blood culture broths. Turbid blood cultures
with Gram-negative bacilli seen on microscopy also underwent B. pseudomallei latex agglutination
and immunoﬂuorescence assay (IFA) testing. The AMD method was as follows: 0.5 ml of turbid blood
culture broth was dispensed into a 1.5-ml Eppendorf tube, 1 drop of lysis buffer was added, and the
suspension was gently mixed using a micropipette; 20 l of suspension was added to 3 drops of
chase buffer in a 0.6-ml Eppendorf tube and mixed by gentle pipetting. The AMD test strip was then
inserted, and the result was read after 15 min according to the manufacturer’s instructions
(Appendix 1). Latex agglutination was performed as previously described (17): 5 l of latex reagent
was mixed with 1 drop of uncentrifuged blood culture broth on a glass slide, which was gently
rocked and observed for agglutination within 2 min. Positive (heat-killed B. pseudomallei) and
negative (heat-killed B. thailandensis) controls were performed each day by mixing 5 l control with
5 l of latex reagent.
IFA, based on a previously described method (18), was performed as follows: 10 l of turbid blood
culture broth was spread on a glass slide to create a thin smear and allowed to air dry. The slide was then
ﬁxed by ﬂooding with absolute methanol for 10 min at room temperature and again allowed to air
dry. Ten microliters of IFA reagent (containing 5 g/ml monoclonal antibody 4B11 and 20 g/ml
Alexa Fluor 488-conjugated goat anti-mouse IgG) was then applied to the smear, and the slide was
covered with a coverslip and incubated at room temperature for 5 min before observation under a
ﬂuorescence microscope (Nikon Eclipse E600 microscope with the U-FL epiﬂuorescence attachment)
at a magniﬁcation of 1,000 using oil immersion. A periphery of bacilli showing strong apple-green
ﬂuorescence was recorded as a positive result (10). Positive results were semiquantiﬁed using a
scheme adapted from the International Union against Tuberculosis and Lung Disease (IUATLD)
guidelines for quantiﬁcation of acid-fast bacilli (AFB) (19) (see Table S3 in the supplemental material).
A minimum of 100 ﬁelds were examined before slides were recorded as IFA negative if no
apple-green ﬂuorescent bacilli were seen. IFA was performed on the same day that the smear was
made whenever possible or the next day if not. Slides of heat-killed (1  106 CFU/ml in PBS at 80°C
for 1 h) B. pseudomallei and B. thailandensis were used as positive and negative controls, respec-
tively, for each batch of immunoﬂuorescence tests. Routine laboratory staff performed the latex
agglutination and AMD tests, while all IFA tests were performed by L. Boutthasavong, blinded to the
latex and AMD test results. All blood culture work was performed in a biosafety cabinet at laboratory
containment level 2 according to normal local practice.
Pus, sputum, and sterile ﬂuid. AMD and IFA were performed on all pus, sputum, and sterile ﬂuid
samples on receipt in the laboratory. Latex agglutination is not validated for these sample types and was
therefore not performed on these samples. IFA was performed as described above using 1 l of sputum,
pus, or sterile ﬂuid sample to make the original smear. AMD was performed as follows: 20 l of pus,
sterile ﬂuid, or thick/viscous sputum samples was mixed with 3 or 4 drops of lysis buffer by vortexing for
15 s. Twenty microliters of this mixture was then added to 3 drops of chase buffer in a 0.6-ml Eppendorf
tube and mixed by gentle pipetting. An AMD test strip was inserted, and the result was read after 15 min.
Thin/watery sputum samples were processed in the same way, except that 50 l of sample was mixed
with 2 or 3 drops of lysis buffer initially. Routine laboratory staff performed AMD tests, while IFA was
performed by L. Boutthasavong, blinded to the results of AMD.
Urine. AMD was performed using 50 l of neat urine, which was added to 3 drops of chase buffer
in a 0.6-ml Eppendorf tube and mixed by gentle pipetting. An AMD test strip was then inserted, and the
result was read after 15 min. AMD tests were performed by routine laboratory staff. If the AMD result for
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neat urine was negative, then urine concentration was performed when concentrators (Minicon B15;
Merck Millipore Ltd.) were available. Five milliliters of urine was concentrated 100 times by using these
simple tabletop concentrators according to the manufacturer’s instructions. AMD was then performed as
described above using 20 l of concentrated urine. Neither latex agglutination nor IFA has been
validated for use directly with urine samples, and therefore neither of these tests was performed on these
samples.
Sera. Admission sera (stored at 80°C) from culture-conﬁrmed melioidosis cases were retrieved, and
AMD was performed as follows: 35 l serum was added to the AMD test strip, followed by 3 drops of
chase buffer. Results were read after 15 min as described previously.
Each new box of AMD test strips underwent quality assurance by testing one strip from the box as
follows: a single colony of a B. pseudomallei-positive control (Lao clinical isolate UI 8976) was emulsiﬁed,
using a sterile loop, in 2 drops of lysis buffer. Three drops of chase buffer was then added to this bacterial
suspension and mixed gently by pipetting before the AMD test strip was inserted and read as previously
described.
Data analysis. The diagnostic sensitivity and speciﬁcity of the AMD, latex agglutination, and IFA on
the different sample types were calculated using culture as the reference standard. The sensitivity and
speciﬁcity of AMD were compared with those of latex agglutination and IFA on turbid blood cultures
containing Gram-negative bacilli and with those of IFA alone for pus, sputum, and sterile ﬂuid samples
using a two-sample test of proportions. In patients conﬁrmed with melioidosis (by culture from any
sample) whose urine was culture negative for B. pseudomallei, a two-sided Fisher’s exact test was used
to analyze the association between urine AMD positivity and (i) disseminated versus localized melioidosis
and (ii) presence or absence of B. pseudomallei bacteremia. Melioidosis cases were deﬁned as “dissem-
inated” when B. pseudomallei bacteremia was present and/or there was clinical/radiological or microbi-
ological evidence of multiple sites of disease. Cases were deﬁned as “localized” if only one site of disease
was present, e.g., pneumonia or parotitis. Analysis was done using STATA, v14.2 (College Station, TX,
USA).
RESULTS
Analytical sensitivity and speciﬁcity. All B. pseudomallei-seeded blood cultures
were AMD positive by 12 h of incubation (see Table S1 in the supplemental material).
The lower limit of detection of the AMD was found to be 1.4  105 CFU/ml, meaning
that it was positive in 3 of 4 seeded blood cultures before they became visibly turbid
and in 4 of 4 seeded blood cultures before organisms were detectable by Gram staining
of the broth. Centrifugation of blood culture broth prior to performing AMD did not
reduce time to positivity.
All non-B. pseudomallei reference strains were negative by AMD (see Table S2 in the
supplemental material). Two soil isolates of B. thailandensis and one sputum isolate of
B. cepacia were AMD positive. All 3 of these isolates were known to give a positive B.
pseudomallei latex agglutination test, probably due to production of a cross-reacting
extracellular polysaccharide (20). All four positive-control B. pseudomallei clinical iso-
lates were positive by AMD.
Prospective evaluation. Between 26 June and 18 December 2014, 89 patients were
diagnosed with melioidosis by culture of B. pseudomallei from at least one sample type
(blood, pus, sputum, sterile ﬂuid, urine, throat swab, wound swab [see Fig. S1 in the
supplemental material]). The median age was 45 years (interquartile range [IQR], 27 to
54 years), 55% were male, and 20/89 (22.5%) patients died while in the hospital or were
discharged moribund. Blood cultures were received from 85 of these patients (85/89,
96%) of whom 54% (46/85) were bacteremic with B. pseudomallei. Of the 43 patients
not found to be bacteremic, 34 had localized disease while 9 had evidence of multifocal
disease.
Turbid blood cultures. There were 412 turbid blood culture bottles during the
study period, of which 4 did not have AMD performed and were therefore excluded;
408 turbid blood culture bottles from 247 patients were thus included in the analysis.
Organisms isolated from the 408 blood cultures are shown in Fig. S2 in the supple-
mental material. B. pseudomallei was isolated from 100 bottles (Fig. 1). The overall AMD
sensitivity was 99% (99/100; 95% conﬁdence interval, 94.6 to 100%) and speciﬁcity was
100% (308/308; 98.8 to 100%). Of these 408 turbid blood culture bottles, 252 had
Gram-negative bacilli (GNB) seen on Gram stain and therefore had additional rapid tests
performed: latex agglutination (n  237) and immunoﬂuorescence assay (IFA; n  176)
(Fig. 1). Sensitivities and speciﬁcities for these tests are given in Table 1. A total of 166
turbid blood culture samples with GNB seen on microscopy had all 3 rapid tests
Woods et al. Journal of Clinical Microbiology
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performed, with agreement between all 3 rapid tests and culture for 98.2% of them
(163/166). One sample was AMD and latex agglutination negative but IFA and B.
pseudomallei culture positive. Two samples were scanty positive by IFA (1 to 3 bacilli/
100 ﬁelds) but negative by all other tests.
FIG 1 Sample ﬂow diagram of turbid blood cultures with Gram-negative bacilli seen on microscopy. In this and all
subsequent ﬁgures, “not documented” means that there was inadequate documentation to include the result in
the analysis; “missed” means that the test was not performed.
TABLE 1 Diagnostic sensitivity and speciﬁcity for all tests and sample types compared
with culture as the reference standarda
Specimen type (n) Test (n) % Sensitivity (95% CI) % Speciﬁcity (95% CI)
Turbid blood
culture with GNB
(252)
AMD (252) 99.0 (94.6–100) 100 (97.6–100)
Latex (237) 99.0 (94.5–100) 100 (97.4–100)
IFA (176) 100 (94.8–100) 98.1 (93.4–99.8)
P value NS* NS**
Pus (139) AMD (139) 47.1 (23.0–72.2) 100 (97.0–100)
IFA (95) 66.7 (29.9–92.5) 90.7 (82.5–95.9)
P value 0.338 0.0006
Sputum (23) AMD (23) 33.3 (0.84–90.6) 100 (83.2–100)
IFA (23) 100 (29.2–100) 85.0 (62.1–96.8)
P value 0.083 0.072
Sterile ﬂuid (46) AMD (46) 0 (0–84.2) 100 (92.0–100)
IFA (43) 100 (15.8–100) 100 (91.4–100)
P value 0.046 1.0
Urine selected (241) AMD (241) 86.7 (59.5–98.3) 90.7 (86.2–94.2)
aNS, not signiﬁcant; CI, conﬁdence interval; n, number of samples. *, P  0.994 for AMD versus latex, 0.402
for latex versus IFA, 0.405 for IFA versus AMD; **, P  1.0 for AMD versus latex, 0.107 for latex versus IFA,
0.169 for IFA versus AMD.
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Pus. Of 150 pus samples received during the study period, 139 had AMD performed
and were included in the analysis. B. pseudomallei was cultured from 17/139 samples.
Ninety-ﬁve of 139 pus samples also underwent IFA (Fig. 2). AMD was signiﬁcantly more
speciﬁc than IFA (P  0.0006; Table 1). However, all 8 false-positive IFA results were
reported as scanty (1 to 5 bacilli/100 ﬁelds).
Sputum. Twenty-six sputa were received during the study period, 3 of which did not
have AMD performed and were excluded. The remaining 23 sputa underwent both
AMD and IFA testing, and no signiﬁcant difference in sensitivity or speciﬁcity was found
(Table 1). Three of 23 samples were B. pseudomallei culture positive, all 3 of which were
IFA positive but only 1 of which was AMD positive (Fig. 3). There were 3 positive IFA
tests from culture-negative samples, but all were reported as scanty (1 to 7 bacilli/100
ﬁelds), and 2 of these samples were from the same patient, who, although culture
negative for B. pseudomallei, had a clinical picture compatible with melioidosis and died
shortly after transfer to Thailand for further health care.
Sterile ﬂuid. Between 10 October and 18 December 2014, 50 sterile ﬂuid samples
were received, and 46 underwent AMD and were included in the analysis (29 pleural
ﬂuid, 6 joint ﬂuid, 2 pericardial ﬂuid, and 9 ascitic ﬂuid smaples); 42 of the 46 also
underwent IFA. B. pseudomallei was isolated from 2 samples (both were joint ﬂuid
samples from the same patient, taken 11 days apart); IFA was positive on both of these
samples, while AMD was negative on both (Fig. 4). The sensitivity of IFA was therefore
signiﬁcantly better than AMD (Table 1), although numbers were small and conﬁdence
intervals wide.
Urine. Between 2 July and 2 September 2014, 249 urine samples were received.
AMD was not performed on 28 of them, and 16 were duplicate specimens; thus, 205
were included in the analysis (Fig. 5). Three of 205 urine samples were B. pseudomallei
FIG 2 Sample ﬂow diagram for pus samples.
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FIG 4 Sample ﬂow diagram for sterile ﬂuid samples.
FIG 3 Sample ﬂow diagram for sputum samples.
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culture positive, 2 of which were AMD positive (sensitivity, 66.7% [9.4 to 99.2%]). The B.
pseudomallei culture-positive urine sample that was AMD negative had a low bacterial
load, with only 1 CFU isolated from a centrifuged deposit. AMD speciﬁcity was 100%
(98.2 to 100%; 202/202). Organisms isolated in culture from all 205 urine samples are
shown in Fig. S3 in the supplemental material.
From 3 September onwards, only selected urine samples were included in the study
(3 September to 18 December 2014, n  102; 23 June to 12 November 2015, n  189).
AMD was not performed on 27 samples (2014, 5 samples; 2015, 22 samples), and 23
samples were duplicates and therefore excluded. Thus, 241 samples were included in
the analysis. Fifteen of 241 urine samples were B. pseudomallei culture positive, 13/15
of which were AMD positive (Table 1). Twenty-one of 226 urine culture-negative
samples were AMD positive (Fig. 6). Interestingly, 19/21 of these urine samples came
from patients who had melioidosis conﬁrmed by culture from another site, suggesting
that these were not “false-positive” AMD results but that the AMD was detecting true
B. pseudomallei antigenuria. The positive predictive value of AMD on urine for correctly
diagnosing melioidosis in this cohort was therefore 94.1% (32/34 [79.7 to 98.5%]) with
a disease prevalence of 35.7% (86/241).
Urine samples from melioidosis cases. To further describe B. pseudomallei anti-
genuria in our cohort, results of urine samples received from the 182 culture-conﬁrmed
(from any site) melioidosis cases during the 2014 and 2015 study periods were analyzed
further. One urine sample (each) was received from 114 (2014, 57; 2015, 57) of these
182 patients, and 20/114 urine samples were culture positive for B. pseudomallei (16/20
were AMD positive). Twenty-one of the 94 culture-negative urine samples were AMD
positive (Table 2). Patients who were urine culture negative for B. pseudomallei but had
disseminated melioidosis were signiﬁcantly more likely to be urine AMD positive than
those with localized melioidosis (18/61 versus 3/32; P  0.036). The presence of B.
pseudomallei bacteremia did not increase the likelihood of urine AMD positivity overall
(15/49 versus 6/44, P 0.08) or in patients with disseminated melioidosis (15/49 versus
3/12, P  1.0).
Urine concentration. Due to the lack of availability of urine concentrators, the urine
concentration assay was performed retrospectively on 20 stored urine isolates collected
FIG 5 Sample ﬂow diagram for unselected urine samples (2 July to 2 September 2014).
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prospectively between 2 July and 18 December 2014. All urine samples were from
conﬁrmed melioidosis cases but were AMD negative on neat urine and B. pseudomallei
urine culture negative. Six of 20 urine samples were AMD positive after urine concen-
tration.
Sera. Seventy-one stored serum samples from the 89 melioidosis cases diagnosed
from 26 June to 18 December 2014 were available for AMD testing (Fig. 7). Five of 71
(7%) samples were AMD positive. Each of these ﬁve patients was culture positive for B.
pseudomallei from blood taken on the same day as the serum sample. Of the patients
negative by AMD on sera, 31/66 had been bacteremic with B. pseudomallei on the same
day as the serum sample was taken, and a further 9 nonbacteremic patients had
evidence of disseminated disease. Sera therefore had low sensitivity for diagnosis of
melioidosis compared with blood culture as the gold standard, 13.9% (5/36; 4.7% to
29.5%).
FIG 6 Sample ﬂow diagram for selected urine samples (3 September to 18 December 2014 and 23 June
to 12 November 2015).
TABLE 2 Urine AMD results according to site of disease in melioidosis cases that were
urine culture negative for B. pseudomalleia
Site of disease (n)
No. of cases with urine AMD result:
Positive Negative
Disseminated (61)
Bacteremic (49) 15 34
Not bacteremic (12) 3 9
Localized (32) 3 29
an, number of patients. The total number of patients was 93; 1 patient did not have sufﬁcient data available
to categorize the site of disease.
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DISCUSSION
We evaluated the accuracy of the AMD lateral ﬂow immunoassay (LFI) for the rapid
diagnosis of melioidosis directly from clinical samples. The LFI detects an extracellular
polysaccharide of B. pseudomallei with a limit of detection (LOD) of 0.2 ng/ml (13, 21).
On turbid blood cultures, the AMD was found to have excellent analytical and diag-
nostic sensitivity and speciﬁcity, comparable to those of both IFA and latex agglutina-
tion, which were found to have performance characteristics similar to those published
in previous studies (11, 17, 18, 22). One turbid blood culture bottle was AMD and latex
agglutination negative but culture positive for B. pseudomallei. After 24 h of further
incubation, both tests were positive on the same bottle, suggesting that the initial
false-negative results may reﬂect an initial bacterial load lower than the limit of
detection for both tests. The high speciﬁcity of the AMD test on turbid blood cultures
is extremely promising for deployment to ﬁeld settings in the tropics, where simple
tests such as AMD may be performed after a broth incubation step in the absence of
laboratory facilities for Gram stain and culture. A positive AMD result, potentially
obtained as early as 12 h following blood sampling, could prove to be life-saving if
antimicrobial treatment is adapted appropriately.
The AMD test maintained excellent analytical and diagnostic speciﬁcity across all
sample types, even “nonsterile” samples such as sputum and urine, which are more
likely to contain contaminating bacteria (including environmental Burkholderia spp. in
a tropical setting of endemicity). False-positive AMD results were seen in our study only
in the case of environmental Burkholderia strains known to express an extracellular
polysaccharide similar to that detected by the AMD. Although this may pose a problem
when AMD is used for detection of B. pseudomallei in environmental samples such as
soil (23), in clinical samples it is rarely likely to be relevant. The ﬁnding of AMD reactivity
in a clinical strain of Burkholderia cepacia in this study is novel, as previous testing of B.
cepacia complex strains had not demonstrated this (D. P. AuCoin, unpublished obser-
vations). Relatively few sputum samples were included in this study, and further work is
needed to investigate how frequently respiratory samples containing non-pseudomallei
Burkholderia (for example, from patients with cystic ﬁbrosis) may cause AMD reactivity.
FIG 7 Sample ﬂow diagram for serum samples from culture-conﬁrmed melioidosis cases diagnosed
between 26 June and 18 December 2014.
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However, in our experience, such strains are rare and the majority of B. cepacia isolates
do not cross-react in this way (data not shown).
AMD analytical sensitivity was extremely promising, with AMD LOD on broth cultures
better than previous estimates of LOD for latex agglutination (1  106 to 2  106 CFU/ml
[22]) and similar to estimated bacterial loads of B. pseudomallei in urine (1.5 104 CFU/ml),
sputum (1.1 105 CFU/ml), and pus (1.1 107 CFU/ml) samples (24). However, diagnostic
sensitivity was disappointing in nonblood culture samples. We observed that viscous
samples were more challenging to process for AMD, and this, coupled with low initial
bacterial loads, may explain the moderate sensitivity observed for the test in these samples.
Seven pus samples in our study were received in broth from distant study sites (and
therefore excluded from the main analysis), and AMD was positive in all 3 samples that
were subsequently B. pseudomallei culture positive. An initial enrichment culture step has
been previously suggested to improve the sensitivity of IFA for B. pseudomallei from
nonblood clinical samples (10). It is likely that broth incubation of pus, sputum, and sterile
ﬂuid found to be AMD negative on direct testing will increase AMD sensitivity on these
samples, while only delaying diagnosis by a few hours, although appropriate laboratory
biosafety equipment and practices would be needed.
IFA diagnostic sensitivity and speciﬁcity in this study were similar to those published
in previous reports (10). However, despite the reportedly lower LOD (2 103 CFU/ml of IFA
[10]), IFA was not found to be signiﬁcantly more sensitive than AMD on any sample type
except sterile ﬂuids, nor was IFA signiﬁcantly more speciﬁc than AMD except on pus
samples. The inherent subjectivity of immunoﬂuorescence microscopy, the possibility of
misidentifying ﬂuorescent debris as bacteria, and the labor- and resource-intensive meth-
odology are important disadvantages of IFA compared with AMD.
The number of B. pseudomallei culture-positive urine samples in this study was limited;
however, the ability of AMD to detect B. pseudomallei antigenuria in melioidosis patients,
particularly those with disseminated melioidosis whose urine is culture negative for B.
pseudomallei, is encouraging. Our ﬁndings replicate previous work in a nonhuman primate
model, in which antigen was detectable in urine by AMD as early as 2 to 3 days after
experimental infection with B. pseudomallei (D. P. AuCoin, unpublished). The extracellular
polysaccharide detected by AMD maintains its molecular weight in urine without degra-
dation over time, which might otherwise affect the sensitivity of AMD on urine (25). Urine
is an easily available, noninvasive sample and a simple matrix for AMD. Reliable urine
antigen detection for melioidosis by a rapid test such as AMD could revolutionize diag-
nostics in resource-limited parts of the world, where this disease is most prevalent.
However, the overall sensitivity of urine AMD for detection of melioidosis in our cohort was
only 33% (37/114; 24 to 41.9%). The use of simple tabletop urine concentrators increased
AMD sensitivity in this study; however, the numbers tested were limited and further work
is needed to establish the extent to which urine concentration improves AMD sensitivity in
urine. At approximately $6/sample, cost may prove a barrier to the use of this concentration
technique for urine samples in settings of endemicity.
The AMD test is an extremely promising tool for diagnosis of melioidosis worldwide
and meets all affordable, sensitive, speciﬁc, user friendly, rapid and robust, equipment-
free, and delivered (ASSURED) criteria for RDTs (26), although further work is required
to optimize sensitivity on nonblood samples. However, it is not yet a true “point of care”
test, with AMD sensitivity on stored whole-blood samples from bacteremic melioidosis
patients having been shown to be 40% (16/40; compared with 20% sensitivity for
molecular detection on the same samples) previously (14) and on stored serum samples
in this study only 7% (5/71). The low bacterial load in blood samples (1 CFU/ml prior to
broth incubation [13]) may limit the utility of the AMD test on these sample types, and
further large-scale prospective evaluations are required. However, the simple nature of
the AMD technology means that it is more likely than molecular diagnostics to be
widely applicable in a developing country context for the foreseeable future.
The main limitation of this study was that not all samples underwent testing by
all the relevant rapid tests. This was partly related to the nature of the study, with
the assays being performed during routine processing in a busy diagnostic labo-
Melioidosis Diagnosis by RDT in Laos Journal of Clinical Microbiology
July 2018 Volume 56 Issue 7 e02002-17 jcm.asm.org 11
 o
n
 June 25, 2018 by Nicholas W
hite
http://jcm.asm.org/
D
ow
nloaded from
 
ratory. However, this study design gave a realistic indication of assay performance
in a routine setting. In addition, the immunoﬂuorescence assay, which had not
previously been routinely used in our laboratory, took longer than expected to
optimize, and therefore turbid blood cultures and pus received in the initial stages
of the study did not undergo IFA. Sputum and sterile ﬂuid analyses were also
limited due to low sample numbers.
In some patients in our study, a positive urine AMD result was the ﬁrst indication
of melioidosis, preceding culture conﬁrmation by at least 24 h and resulting in an
early switch to appropriate antibiotics in critically unwell patients. This study was
not designed to evaluate the clinical impact of obtaining a rapid diagnosis of
melioidosis by AMD; however, now that we have shown the diagnostic speciﬁcity of
this test to be excellent, we are further investigating this. Throat swabs are another
easily obtained sample type that is routinely used for diagnosis of melioidosis by
culture in our setting. Incubation of a throat swab in liquid selective enrichment
broth such as SBCT (8) would enable throat swabs to be used for rapid diagnosis of
melioidosis by AMD, and this also warrants further study.
In conclusion, the AMD has excellent sensitivity and speciﬁcity for early detection of
B. pseudomallei in blood culture broth. It also has the advantage over the latex
agglutination test that it can be used directly on other sample types for the diagnosis
of melioidosis. Speciﬁcity is retained when used directly on these other samples, but
sensitivity is only moderate and requires optimization. The ability to identify melioidosis
from urine samples by using AMDmay signiﬁcantly enhance diagnosis of this neglected
disease. Studies are needed in a variety of different prevalence settings in order to truly
understand the utility of this assay; however, deployment of the AMD test globally
might improve our understanding of the epidemiology of melioidosis. Ultimately, we
hope to see LFI technology used for multiplex antigen detection of a number of
important causes of febrile illness in resource-limited settings.
APPENDIX 1
Interpretation of AMD reactivity. In Fig. A1, interpretation according to the
manufacturer’s instructions is shown. Note that a faint test line is considered positive,
as the red color in this region varies depending on the concentration of antigen
present. Examples of positive AMD results are given in Fig. A2.
FIG A1 Interpretation according to the instructions of the manufacturer (InBios). C, control line; T, test line.
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